FIELD: chemistry.
SUBSTANCE: in compounds of formula (I) 
, Q is: (IIa) 
or (IIb) 
, R1 is chosen from a group which consists of carboxylic aryl and carboxylic aryl which is substituted with substitute(s) independently chosen from a group which consists of halogen, cyano, nitro, C1-10alkyl, C1-10alkyl which is substituted with substitute(s) independently chosen from a group which consists of halogen, C1-9alkoxy, C1-9alkoxy which is substituted with substitute(s) independently chosen from a group which consists of halogen, mono-C1-5alkylamino, and heterocyclyl or heterocyclyl which is substituted with substitute(s) independently chosen from a group which consists of halogen, C1-5alkyl; R2 is C1-5alkyl, C1-5alkyl which is substituted with halogen, C1-5alkyl which is substituted with carboxylic aryl, C1-5alkoxy, -N(R2a)(R2b); where R2a and R2b are each independently hydrogen, C1-5alkyl or C1-5alkyl, substituted with substitute(s) independently chosen from a group which consists of hydroxyl, carboxylic aryl; L represents formula (IIIa); 
, where R3 and R4 are each hydrogen; A is a single bond, and B is a single bond or -CH2-; Z1, Z3, and Z4 are each independently hydrogen, halogen, C1-5alkyl, C1-5alkyl, substituted with carboxylic aryl, C1-5alkoxy, mono-C1-5alkylamino, di-C1-5alkylamino, carboxylic aryl, heterocyclyl or substituted heterocyclyl; Z2 is hydrogen, C1-5alkyl, C1-5alkyl which is substituted with carboxylic aryl, C1-5alkoxy, mono-C1-5alkylamino, di-C1-5alkylamino, carboxylic aryl, heterocyclyl or substituted heterocyclyl; Y is -C(O)NH-, -C(O)-, -C(S)NH-, -C(O)O- or -CH2-; where carboxylic aryl is phenyl; heterocyclyl is 1H-indolyl, 9H- xanthenyl, benzo[1,3]dioxolyl, furyl, imidazolyl, isoxazolyl, morpholinyl, piperazinyl, pyridyl, pyrrolidyl; halogen is fluorine, chlorine, bromine or iodine. The invention also relates to a pharmaceutical composition.
EFFECT: compounds can be used for treating central nervous system diseases, and for improving memory functioning, sleep, awakening, diabetes.
16 cl, 8 dwg, 4 tbl, 525 ex
| Title | Year | Author | Number |
|---|---|---|---|
| QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING SAME | 2011 |
|
RU2582610C2 |
| PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | 2013 |
|
RU2661896C2 |
| COMPOUNDS AND COMPOSITIONS FOR MODULATING KINASE ACTIVITY OF EGFR MUTANTS | 2015 |
|
RU2822389C2 |
| COMPOUNDS AND A COMPOSITION FOR MODULATING THE KINASE ACTIVITY OF EGFR MUTANTS | 2015 |
|
RU2727700C2 |
| BICYCLIC COMPOUND AND USE THEREOF FOR SUV39H2 INHIBITION | 2016 |
|
RU2729187C1 |
| TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | 2009 |
|
RU2561104C2 |
| [1,8]NAPHTHYRIDINE DERIVATIVES, USEFUL AS INHIBITORS OF HCV VIRUS REPLICATION | 2006 |
|
RU2467007C2 |
| NEW NICOTINAMIDE DERIVATIVE OR SALT THEREOF | 2011 |
|
RU2560163C2 |
| PIPERIDINE DERIVATIVES | 2011 |
|
RU2554353C2 |
| 1,5-NAPHTHRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THEM | 2012 |
|
RU2645339C1 |
